Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( 🔒 ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Need Help

A Robust, Secure Framework to Effortlessly Bind Distributed Databases and Analysis Tools into Tightly Integrated Translational Drug Discovery Computational Platforms

Award Number: R44TR003022
ORGANIZATION: NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 08/15/2019
PERIOD OF PERFORMANCE END DATE: 07/31/2024

Group Awards By:

View Award Description

A Robust, Secure Framework to Effortlessly Bind Distributed Databases and Analysis Tools into Tightly Integrated Translational Drug Discovery Computational Platforms - PROJECT SUMMARY Collaborative Drug Discovery, Inc. (CDD) proposes to develop Cloud Workspaces for Drug Discovery – a novel informatics framework that will enable scientists engaged in drug discovery and translation to effort- lessly, robustly, and securely integrate disparate databases and computational tools distributed across multiple systems and vendors into highly-efficient, custom-tailored computational workflows. Our innovative technol- ogy will solve a critical problem that hinders drug discovery and translation efforts: scientists in this field typi- cally need to combine chemical and biological data from several sources, run them through multiple software packages that specialize in different types of analyses and visualization, then ideally store the results of the analyses together with their underlying experimental data. Today, this type of integration is difficult and expensive to accomplish and typically fragile, creating a large barrier to (i) exploiting the rapidly increasing number of high-quality public-access data repositories and (ii) evaluating promising new analytical tools and strategies. Monolithic platforms offer to solve this problem by bringing everything together under one roof, but they are extremely expensive and they limit flexibility: no single platform can offer every capability. The alter- native approach – stringing together discrete resources – evolved during the era of desktop computing and does not translate well to modern cloud-based workflows and in particular to the challenges of performing computationally intensive operations that require combining large datasets distributed across remote systems. Cloud Workspaces (CW) aims to combine the strengths and avoid the weaknesses of these two extremes. CW will in essence allow users to easily create their own individualized cloud-hosted solutions tailored to their unique requirements and workflows. Our approach offers the performance, robustness, and ease of use of a monolithic software solution, but without the associated inflexibility and vendor lock in. It offers the flexibility and openness of combining discrete resources, but without the associated integration challenges and fragility, and it advances the pipelining approach to embrace cloud-based models and to encompass distributed data resources without compromising performance or security. In Phase 1 we proved that we could robustly and efficiently synchronize biological and chemical data (transferring only new or modified data while retaining correct association of chemical identifiers) between the CW container environment and remote databases, which was a challenging but essential prerequisite for our concept. In Phase 2 we will complete development of CW and demonstrate its effectiveness with multiple real-world applications together with software application partners and beta customer end users. The market for the technology ranges from academics to small and medium size companies to the large pharmaceutical firms.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2024 ( Subtotal = $0 )
2024	2023	COLLABORATIVE DRUG DISCOVERY, INC.	1633 BAYSHORE HWY	BURLINGAME	CA	94010	SAN MATEO	USA	National Center for Advancing Translational Sciences	000	3	8/22/2024	NON-COMPETING CONTINUATION	$0
														Subtotal = $0

Issue Date FY: 2023 ( Subtotal = $854,888 )
2023	2023	COLLABORATIVE DRUG DISCOVERY INC	1633 BAYSHORE HWY	BURLINGAME	CA	94010	SAN MATEO	USA	National Center for Advancing Translational Sciences	000	3	7/31/2023	NON-COMPETING CONTINUATION	$854,888
														Subtotal = $854,888

Issue Date FY: 2022 ( Subtotal = $854,888 )
2022	2022	COLLABORATIVE DRUG DISCOVERY, INC.	1633 BAYSHORE HWY STE 342	BURLINGAME	CA	94010	SAN MATEO	USA	National Center for Advancing Translational Sciences	000	2	8/17/2022	COMPETING CONTINUATION	$854,888
														Subtotal = $854,888

Grand Total All Awards = $1,709,776

Top

All Categories

About

Search

Reports

Data Submission

Award Information

A Robust, Secure Framework to Effortlessly Bind Distributed Databases and Analysis Tools into Tightly Integrated Translational Drug Discovery Computational Platforms

Award Number: R44TR003022

ORGANIZATION: NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 08/15/2019

PERIOD OF PERFORMANCE END DATE: 07/31/2024

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer